AC Immune Holds Annual General Meeting of Shareholders
23 juin 2023 16h30 HE
|
AC Immune SA
AC Immune Holds Annual General Meeting of Shareholders Shareholders approved all resolutions as proposed by the Board of Directors Lausanne, Switzerland, June 23, 2023 – AC Immune SA (NASDAQ:...
Landmark Study Investigating Novel Alzheimer’s Biomarkers Advances to Data Analysis Stage
14 juin 2023 06h00 HE
|
Global Alzheimer's Platform Foundation
WASHINGTON, DC, June 14, 2023 (GLOBE NEWSWIRE) -- Up to 50 percent of people in the U.S. with Alzheimer’s receive an imprecise or inaccurate diagnosis of their cognitive condition. The tools...
Global Immunoassay for Neurological Biomarkers Market to 2030: Increasing Prevalence of Neurological Diseases Fuels the Sector
05 juin 2023 05h08 HE
|
Research and Markets
Dublin, June 05, 2023 (GLOBE NEWSWIRE) -- The "Immunoassay for Neurological Biomarkers Market Size, Share & Trends Analysis Report By Product, By Disease (Alzheimer's Disease, Parkinson's...
DAVOS ALZHEIMER'S COLLABORATIVE HOSTS GLOBAL MEETING ON THE POWER OF HEALTH TECHNOLOGY FOR ALZHEIMER'S
31 mai 2023 18h13 HE
|
Davos Alzheimer's Collaborative
New York, NY, May 31, 2023 (GLOBE NEWSWIRE) -- The Davos Alzheimer’s Collaborative (DAC) will hold the fourth meeting of its Healthcare System Preparedness Learning Laboratory “The Power of...
Vaccinex Reports First Quarter 2023 Financial Results and Provides Corporate Update
15 mai 2023 16h45 HE
|
Vaccinex, Inc.
Significant YTD Progress in Neurology and Oncology Programs New financing of $5MM closed without warrants, derivatives or other financial considerations ROCHESTER, N.Y., May 15, 2023 (GLOBE...
Neuronic and Santa Clara University partner to develop next-gen neurotech for photobiomodulation guided by real-time brain activity
11 mai 2023 12h00 HE
|
Neuronic Devices Operations GmbH
Integrating photobiomodulation with neurofeedback will revolutionize treatment of brain disorders SANTA CLARA, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- Neuronic, a multi-national company focused...
SciSparc Completed Treatment of Last Patient Enrolled for its Phase IIa Clinical Trial for Alzheimer's Disease and Agitation
02 mai 2023 07h25 HE
|
SciSparc Ltd
The Company previously announced positive interim results from the trial meeting its primary endpoints TEL AVIV, Israel, May 02, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or...
AC Immune Reports First Quarter 2023 Financial Results and Provides a Corporate Update
28 avr. 2023 07h00 HE
|
AC Immune SA
AC Immune Reports First Quarter 2023 Financial Results and Provides a Corporate Update ACI-24.060 anti-Abeta vaccine showed positive initial safety and immunogenicity in first Alzheimer’s disease...
Athira Pharma Presents New Clinical and Preclinical Data at the American Academy of Neurology (AAN) 2023 Annual Meeting
25 avr. 2023 16h01 HE
|
Athira Pharma, Inc.
Fosgonimeton improves MMSE (mini-mental state evaluation) after six months in a post hoc analysis from the Phase 2 ACT-AD trial in mild-to-moderate Alzheimer’s disease Preclinical findings with...
Vaccinex Completes Enrollment in Phase 1b/2 SIGNAL-AD (Alzheimer’s Disease) Study of Pepinemab
25 avr. 2023 08h00 HE
|
Vaccinex, Inc.
Topline data anticipated in mid-2024 SIGNAL-AD builds on promising data from the Phase 2 SIGNAL Study in Huntington’s Disease ROCHESTER, N.Y., April 25, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc....